Chronisch Lymphatische Leukämie: Studienergebnisse - Rezidiv

00:00 Welcome by Johannes Förner (German Cancer Research Center) and Prof. Dr. Barbara Eichhorst (University Hospital of Cologne) 01:49 Presentation of the ERIC study (S151) 04:24 Conclusion on the ERIC study (S151) 05:01 Presentation of the BRUIN CLL-322 study 07:54 Conclusion on the BRUIN CLL-322 study 08:39 Presentation of the HOVON 165/AETHER study 11:04 Conclusion on the HOVON 165/AETHER study 11:22 Presentation of the REFRACTORY CLL study 14:04 Conclusion on the REFRACTORY CLL study 14:50 Questions and discussion on the presented studies 15:18 How likely is it that venetoclax-based therapy will remain effective for a sufficient duration? What alternatives are there? 18:23 Venetoclax alone or with antibodies? What role do TP53 deficiency or other high-risk characteristics play? 19:46 Discussion of the BRUIN CLL-322 trial 22:28 Discussion of the HOVON 165/AETHER trial 24:57 Discussion of the REFRACTORY CLL trial 29:33 Closing remarks - Send us your feedback by email! [email protected]